SYROS PHARMACEUTICALS

Syros Pharmaceuticals is a biopharmaceutical company engaged in the non-coding regulatory region of the genome to develop a new wave of medicines that control the expression of genes. The company's primary product candidates are: SY-1425, a selective retinoic acid receptor alpha agonist that is used to treat acute myeloid leukemia patients; SY-1365, a selective inhibitor of cyclin-dependent kinase 7 (CDK7), that is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors; and SY-5609, a CDK7 inhibitor that can be administered orally, which is being evaluated in investigational new drug application, enabling preclinical studies.
  • TickerSYRS
  • ISINUS87184Q1076
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
SYRS SYROS PHARMACEU... (Health Care)

Syros Pharmaceuticals Inc: 3 directors sold/sold after exercising opti...

Three Directors at Syros Pharmaceuticals Inc sold/sold after exercising options 181,067 shares at between 12.590USD and 13.095USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where tradin...

David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
SYRS SYROS PHARMACEU... (Health Care)

Syros Pharmaceuticals Inc: 3 directors sold/sold after exercising opti...

Three Directors at Syros Pharmaceuticals Inc sold/sold after exercising options 181,067 shares at between 12.590USD and 13.095USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where tradin...

David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
SYRS SYROS PHARMACEU... (Health Care)

Syros Pharmaceuticals Inc: 3 directors sold/sold after exercising opti...

Three Directors at Syros Pharmaceuticals Inc sold/sold after exercising options 181,067 shares at between 12.590USD and 13.095USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where tradin...

David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
SYRS SYROS PHARMACEU... (Health Care)

Syros Pharmaceuticals Inc: 3 directors sold/sold after exercising opti...

Three Directors at Syros Pharmaceuticals Inc sold/sold after exercising options 181,067 shares at between 12.590USD and 13.095USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where tradin...

David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
David Nierengarten ... (+2)
  • David Nierengarten
  • Matthew Barcus
SYRS SYROS PHARMACEU... (Health Care)

Syros Pharmaceuticals Inc: 3 directors sold/sold after exercising opti...

Three Directors at Syros Pharmaceuticals Inc sold/sold after exercising options 181,067 shares at between 12.590USD and 13.095USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where tradin...

David Nierengarten ... (+3)
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus

ResearchPool Subscriptions

Get the most out of your insights

Get in touch